<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01333696</url>
  </required_header>
  <id_info>
    <org_study_id>HNTG 11-01</org_study_id>
    <nct_id>NCT01333696</nct_id>
  </id_info>
  <brief_title>Pemetrexed as Salvage Treatment in Squamous Cell Carcinoma of Head and Neck</brief_title>
  <official_title>Phase II Study of Pemetrexed Monotherapy in Patients With Platinum-resistant Squamous Cell Carcinoma of Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the efficacy and safety of pemetrexed monotherapy as&#xD;
      salvage treatment in patients with relapsed or metastatic squamous cell carcinoma of head and&#xD;
      neck.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The treatment option in patients with platinum-resistant relapsed or metastatic squamous cell&#xD;
      carcinoma of head and neck is limited. Previous randomized phase III study showed a&#xD;
      borderline benefit of pemetrexed added to cisplatin. Therefore, we aim to evaluate the&#xD;
      efficacy of pemetrexed in salvage setting.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">April 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median progression-free survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median overall survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Squamous Cell Carcinoma of Head and Neck</condition>
  <arm_group>
    <arm_group_label>Pemetrexed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mg/m2, repeated every 3 weeks until disease progression or intolerable toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Pemetrexed 500 mg/m2 at day 1. Frequence of cycles: every 3 weeks</description>
    <arm_group_label>Pemetrexed</arm_group_label>
    <other_name>Alimta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age range: 18-65 years old&#xD;
&#xD;
          -  Histological confirmed incurable relapsed or metastatic squamous cell carcinoma of&#xD;
             head and neck&#xD;
&#xD;
          -  Prior exposure of at least one line of platinum-containing regimen&#xD;
&#xD;
          -  At least one site of measurable disease according to RECIST criteria&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Life expectancy of more than 3 months&#xD;
&#xD;
          -  Bone marrow function: ANC≧1.5×109/L, PLT≧100×109/L, Hb≧80g/L&#xD;
&#xD;
          -  Liver function: total bilirubin, ALT and AST &lt;1.5×UNL&#xD;
&#xD;
          -  Renal function: Cr&lt;1.5×UNL, CCR≧45ml/min&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  With curable treatment option&#xD;
&#xD;
          -  Prior platinum exposure only in neo-adjuvant/adjuvant setting or concurrently used&#xD;
             with radiotherapy&#xD;
&#xD;
          -  History of other malignancies except cured basal cell carcinoma of skin and carcinoma&#xD;
             in-situ of uterine cervix&#xD;
&#xD;
          -  Significant active infection&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ye Guo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ye Guo, MD</last_name>
    <phone>86 21 64175590</phone>
    <phone_ext>8906</phone_ext>
    <email>pattrick_guo@msn.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ye Guo, MD</last_name>
      <phone>86 21 64175590</phone>
      <phone_ext>8906</phone_ext>
      <email>pattrick_guo@msn.com</email>
    </contact>
    <investigator>
      <last_name>Ye Guo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>April 11, 2011</study_first_submitted>
  <study_first_submitted_qc>April 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2011</study_first_posted>
  <last_update_submitted>March 2, 2013</last_update_submitted>
  <last_update_submitted_qc>March 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Ye Guo</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Squamous cell carcinoma of head and neck</keyword>
  <keyword>Pemetrexed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

